These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2214548)

  • 1. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy.
    Coburn JW
    Kidney Int Suppl; 1990 Sep; 29():S54-61. PubMed ID: 2214548
    [No Abstract]   [Full Text] [Related]  

  • 2. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulse dose oral calcitriol therapy for renal osteodystrophy: literature review and practice recommendations.
    Dahl NV; Foote EF
    ANNA J; 1997 Oct; 24(5):550-5. PubMed ID: 9392738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
    Arora N; Sandroni S; Moles K
    Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous versus oral calcitriol therapy: is there a clinical difference?
    Lantz JP
    Nephrol News Issues; 1992 Sep; 6(9):38-41. PubMed ID: 1407072
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH; Mawad H; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose vitamin D analogues for renal osteodystrophy.
    Lancet; 1989 Jun; 1(8651):1364-5. PubMed ID: 2567378
    [No Abstract]   [Full Text] [Related]  

  • 10. Calcitriol oral pulse therapy in children with renal osteodystrophy.
    Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
    Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study.
    Mazzaferro S; Pasquali M; Ballanti P; Bonucci E; Di Sanza P; Sardella D; Taggi F; Coen G
    Miner Electrolyte Metab; 1994; 20(3):122-9. PubMed ID: 7816000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal insufficiency.
    Trachtman H; Gauthier B
    J Pediatr; 1987 Jun; 110(6):966-70. PubMed ID: 3585613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of vitamin D analogs in renal osteodystrophy.
    Johnson WJ
    Semin Nephrol; 1986 Mar; 6(1):31-41. PubMed ID: 3037668
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral and parenteral calcitriol for the management of end-stage renal disease.
    Coburn JW; Salusky IB; Norris KC; Goodman WG
    Contrib Nephrol; 1991; 90():166-82. PubMed ID: 1959343
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy.
    Goodman WG; Salusky IB
    Contrib Nephrol; 1991; 90():189-95. PubMed ID: 1959345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guidelines for effective treatment of the osteodystrophic uraemic syndrome with intravenous calcitriol.
    Cannella G; Moriero E; Rolla D
    Nephrol Dial Transplant; 1996; 11 Suppl 3():50-3. PubMed ID: 8840313
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol.
    Hodson EM; Evans RA; Dunstan CR; Hills E; Wong SY; Rosenberg AR; Roy LP
    Clin Nephrol; 1985 Oct; 24(4):192-200. PubMed ID: 3877585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal osteodystrophy: role of calcimimetics.
    Hörl WH
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S104-7. PubMed ID: 12612964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.